They have invented the physical kit and run it through multiple...

They have invented the physical kit and run it through multiple large trials. Now they are improving it with automatisation, which is a very good move.

Automation means they need to start from the beginning with the IVDR regulatory approval process, the new European standard, which is the board's strategic plan. Dr Rachel David would have contributed valuable knowledge to this plan. Her departure represents job done, and a salary cost saving for the company.

The choice of CEO will be very important, worth waiting for the right person. Also the engagement of a US based Contract Manufacturing Organisation to ensure thorough data is available for the IVDR application. This is where they previously failed, the Australian company Sonic not being up to the task.

I believe OB realised that the process to market was going to take longer than expected when he sold 17% of his shares. I wouldn't say this quantity is a 'substantial' portion, nor does it reflect a belief that the company is unable to succeed.